Literature DB >> 26189209

EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study.

Martijn Arns1, Gerard Bruder2, Ulrich Hegerl3, Chris Spooner4, Donna M Palmer5, Amit Etkin6, Kamran Fallahpour7, Justine M Gatt8, Laurence Hirshberg9, Evian Gordon4.   

Abstract

OBJECTIVE: To determine whether EEG occipital alpha and frontal alpha asymmetry (FAA) distinguishes outpatients with major depression (MDD) from controls, predicts antidepressant treatment outcome, and to explore the role of gender.
METHODS: In the international Study to Predict Optimized Treatment in Depression (iSPOT-D), a multi-center, randomized, prospective open-label trial, 1008 MDD participants were randomized to escitalopram, sertraline or venlafaxine-extended release. The study also recruited 336 healthy controls. Treatment response was established after eight weeks and resting EEG was measured at baseline (two minutes eyes open and eyes closed).
RESULTS: No differences in EEG alpha for occipital and frontal cortex, or for FAA, were found in MDD participants compared to controls. Alpha in the occipital and frontal cortex was not associated with treatment outcome. However, a gender and drug-class interaction effect was found for FAA. Relatively greater right frontal alpha (less cortical activity) in women only was associated with a favorable response to the Selective Serotonin Reuptake Inhibitors escitalopram and sertraline. No such effect was found for venlafaxine-extended release.
CONCLUSIONS: FAA does not differentiate between MDD and controls, but is associated with antidepressant treatment response and remission in a gender and drug-class specific manner. SIGNIFICANCE: Future studies investigating EEG alpha measures in depression should a-priori stratify by gender.
Copyright © 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alpha; Alpha asymmetry; Antidepressant; Depression; EEG; Gender; Major depressive disorder; Personalized medicine; QEEG; iSPOT-D

Mesh:

Substances:

Year:  2015        PMID: 26189209     DOI: 10.1016/j.clinph.2015.05.032

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  41 in total

1.  Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial.

Authors:  Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter
Journal:  J Psychiatr Res       Date:  2020-02-26       Impact factor: 4.791

Review 2.  Computational psychiatry as a bridge from neuroscience to clinical applications.

Authors:  Quentin J M Huys; Tiago V Maia; Michael J Frank
Journal:  Nat Neurosci       Date:  2016-03       Impact factor: 24.884

3.  Women with Major Depressive Disorder, Irrespective of Comorbid Anxiety Disorders, Show Blunted Bilateral Frontal Responses during Win and Loss Anticipation.

Authors:  Jennifer L Stewart; Evan J White; Rayus Kuplicki; Elisabeth Akeman; Jerzy Bodurka; Yoon-Hee Cha; Justin S Feinstein; Sahib S Khalsa; Jonathan B Savitz; Teresa A Victor; Martin P Paulus; Robin L Aupperle
Journal:  J Affect Disord       Date:  2020-05-11       Impact factor: 4.839

4.  Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response.

Authors:  Craig E Tenke; Jürgen Kayser; Pia Pechtel; Christian A Webb; Daniel G Dillon; Franziska Goer; Laura Murray; Patricia Deldin; Benji T Kurian; Patrick J McGrath; Ramin Parsey; Madhukar Trivedi; Maurizio Fava; Myrna M Weissman; Melvin McInnis; Karen Abraham; Jorge E Alvarenga; Daniel M Alschuler; Crystal Cooper; Diego A Pizzagalli; Gerard E Bruder
Journal:  Psychophysiology       Date:  2017-01       Impact factor: 4.016

5.  Frontal theta and posterior alpha in resting EEG: A critical examination of convergent and discriminant validity.

Authors:  Ezra E Smith; Craig E Tenke; Patricia J Deldin; Madhukar H Trivedi; Myrna M Weissman; Randy P Auerbach; Gerard E Bruder; Diego A Pizzagalli; Jürgen Kayser
Journal:  Psychophysiology       Date:  2019-10-02       Impact factor: 4.016

6.  Resting frontal brain asymmetry is linked to future depressive symptoms in women.

Authors:  Jennifer L Stewart; John J B Allen
Journal:  Biol Psychol       Date:  2018-06-18       Impact factor: 3.251

Review 7.  Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression.

Authors:  Candace Jones; Charles B Nemeroff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis.

Authors:  Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2018-10-03       Impact factor: 18.112

9.  Intracranial source activity (eLORETA) related to scalp-level asymmetry scores and depression status.

Authors:  Ezra E Smith; James F Cavanagh; John J B Allen
Journal:  Psychophysiology       Date:  2017-10-11       Impact factor: 4.016

10.  Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG.

Authors:  Salvatore Campanella; Kemal Arikan; Claudio Babiloni; Michela Balconi; Maurizio Bertollo; Viviana Betti; Luigi Bianchi; Martin Brunovsky; Carla Buttinelli; Silvia Comani; Giorgio Di Lorenzo; Daniel Dumalin; Carles Escera; Andreas Fallgatter; Derek Fisher; Giulia Maria Giordano; Bahar Guntekin; Claudio Imperatori; Ryouhei Ishii; Hendrik Kajosch; Michael Kiang; Eduardo López-Caneda; Pascal Missonnier; Armida Mucci; Sebastian Olbrich; Georges Otte; Andrea Perrottelli; Alessandra Pizzuti; Diego Pinal; Dean Salisbury; Yingying Tang; Paolo Tisei; Jijun Wang; Istvan Winkler; Jiajin Yuan; Oliver Pogarell
Journal:  Clin EEG Neurosci       Date:  2020-09-25       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.